Engine Biosciences bags $27M Series A extension to advance precision medicine platform in oncology

Engine Biosciences has raised $27 million in a Series A extension with an eye to advance its discovery-stage precision oncology programs, which leverage both machine learning and CRISPR screening technology.

The extension raise was led by Polaris Partners with support from existing investors ClavystBio, Invus and EDBI, as well as new backers Coronet Ventures and SEEDS Capital. It brings the total funds raised by the trans-Pacific biotech since inception to $86 million, including $70 million in total Series A proceeds.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。